Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis

医学 肉芽肿伴多发性血管炎 美罗华 内科学 显微镜下多血管炎 养生 抗中性粒细胞胞浆抗体 血管炎 环磷酰胺 临床终点 肾脏疾病 胃肠病学 外科 随机对照试验 疾病 化疗 淋巴瘤
作者
Sophie Nagle,Yann Nguyen,Mary‐Jane Guerry,T. Quéméneur,Dimitri Titeca‐Beauport,Thomas Crépin,Rafik Mesbah,Idris Boudhabhay,G. Pugnet,Céline Lebas,A. Néel,Alexandre Karras,É. Hachulla,Juliette Woessner,Vincent Pestre,Raphaël Borie,S. Vinzio,Jean-Baptiste Gouin,Sara Melboucy‐Belkhir,R. Outh
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:84 (2): 319-328 被引量:2
标识
DOI:10.1136/ard-2024-226339
摘要

Background

The PEXIVAS (Plasma exchange and glucocorticoids in severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis) trial showed that a reduced-dose glucocorticoid regimen (redGC) was non-inferior to a standard-dose regimen (standGC) with respect to death or end-stage kidney disease (ESKD) in patients with ANCA-associated vasculitis (AAV). However, the primary endpoint did not include disease progression or relapse, cyclophosphamide was the main induction therapy and rituximab (RTX)-treated patients tended to have a higher risk of death or ESKD with redGC. We aimed to evaluate the real-world use of redGC.

Methods

We conducted a retrospective, multicentre study comparing PEXIVAS redGC with standGC in patients with AAV. The primary composite outcome was the occurrence of death, ESKD, AAV progression before remission or relapse within the 12 months following induction. Inverse probability of treatment weighting was used to correct for baseline imbalance between groups. Factors associated with the occurrence of the primary outcome were estimated.

Results

A total of 234 patients were included. The primary composite outcome occurred in 42/126 (33%) patients with redGC versus 20/108 (19%) with standGC. In unweighted multivariable analysis and in weighted analysis, redGC was independently associated with the primary outcome but not with death or ESKD. Among redGC-treated patients, those with serum creatinine>300 µmol/L were more likely to achieve the primary outcome. RTX-treated patients who received redGC were more likely to experience death or ESKD and to achieve the primary outcome.

Conclusion

In this study of patients with AAV primarily treated with RTX, redGC was associated with an increased risk of the primary outcome consisting of death, ESKD, AAV progression before remission or relapse.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lc发布了新的文献求助10
1秒前
zcg完成签到 ,获得积分10
1秒前
1秒前
Avvei完成签到,获得积分10
2秒前
4秒前
乐乐应助Dr.Liujun采纳,获得10
4秒前
伟大的鲁路皇完成签到,获得积分10
4秒前
生动茹妖完成签到,获得积分10
4秒前
完美世界应助南瓜气气采纳,获得30
5秒前
5秒前
6秒前
jinyue完成签到,获得积分10
8秒前
hh发布了新的文献求助10
9秒前
11秒前
lc完成签到,获得积分10
13秒前
16秒前
李健的小迷弟应助anna采纳,获得10
17秒前
量子星尘发布了新的文献求助10
17秒前
19秒前
19秒前
嘀嘀咕咕发布了新的文献求助10
19秒前
大观天下完成签到,获得积分10
19秒前
科研通AI2S应助科研通管家采纳,获得10
20秒前
英姑应助科研通管家采纳,获得10
20秒前
科研通AI5应助科研通管家采纳,获得10
20秒前
20秒前
科研通AI2S应助科研通管家采纳,获得10
20秒前
共享精神应助科研通管家采纳,获得10
20秒前
科目三应助科研通管家采纳,获得10
20秒前
bkagyin应助科研通管家采纳,获得10
20秒前
SciGPT应助科研通管家采纳,获得10
20秒前
CodeCraft应助科研通管家采纳,获得10
20秒前
orixero应助科研通管家采纳,获得10
21秒前
脑洞疼应助科研通管家采纳,获得10
21秒前
21秒前
兴奋千兰发布了新的文献求助10
22秒前
有机发布了新的文献求助10
23秒前
yukang发布了新的文献求助10
23秒前
25秒前
大观天下发布了新的文献求助30
26秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989069
求助须知:如何正确求助?哪些是违规求助? 3531351
关于积分的说明 11253589
捐赠科研通 3269939
什么是DOI,文献DOI怎么找? 1804851
邀请新用户注册赠送积分活动 882074
科研通“疑难数据库(出版商)”最低求助积分说明 809073